Breaking News, Collaborations & Alliances

RS BioTherapeutics Partners with Recipharm for Product Characterization of RSBT-001

Takes important step towards filing an IND for RSBT-001 in the treatment of COPD.

Author Image

By: Charlie Sternberg

Associate Editor

RS BioTherapeutics, whose mission is to harness its understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, has selected Recipharm, a leading Contract Development and Manufacturing Organization (CDMO), as its partner to conduct product characterization for its investigational compound, RSBT-001.   Product characterization is an important next step for RSBT-001 before filing...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters